source
- FDA rejects Summit’s ivonescimab, citing China‑centric data and missed survival benefitThe FDA sent Summit Therapeutics a complete response letter on Nov 13, rejecting its PD‑1×VEGF bispecific antibody ivonescimab. Reviewers said the pivotal HARMONi trial was dominated by patients f…
- Capsida proposes new monkey testing framework after fatal gene therapy trial for brain diseaseResearchers presented investigations into a patient death that occurred in a gene therapy trial for a brain disease, which had raised concerns in the field. While the exact cause of death was not…